SecBot SecBot

NBIX drug pipeline

$165.31
−1.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.9%
1-day, median of 3 events
IV rank
21
IV 30% · HV 47%
Rated drugs
9
1 mixed · 8 neutral
Phase 3 trials
7
5 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.

direclidine Updated Nov 3

What to watch

The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.

Bull case
  • Direclidine is a selective M4 orthosteric agonist, a differentiated mechanism from Cobenfy (which combines M1/M4 agonism with a peripheral blocker). If direclidine shows a cleaner side-effect profile or once-daily dosing advantage, it could carve out a meaningful share of the large schizophrenia market.
  • Phase 2 data showed a statistically significant 7.5-point PANSS improvement at the 20 mg dose (p=0.011, effect size 0.61) with generally good tolerability, providing a solid foundation for the Phase 3 registrational program.
  • Neurocrine is a well-capitalized company with INGREZZA generating over $1.1B in quarterly revenue, giving it the resources to fully commercialize direclidine without partnership dependence.
Bear case
  • Direclidine faces a first-mover disadvantage: Bristol Myers Squibb's Cobenfy (KarXT, xanomeline/trospium) was FDA-approved for schizophrenia in September 2024 and is already on the market, establishing the muscarinic agonist class and potentially capturing prescriber mindshare before direclidine can reach Phase 3 readout.
  • Phase 3 trials in schizophrenia are notoriously high-risk; the Phase 2 study showed statistical significance only at the 20 mg dose (not at higher doses), raising questions about the therapeutic window and dose-response curve.
  • Topline data from the ongoing Phase 3 program is not expected until 2027 at the earliest, and some trials may read out as late as 2028, meaning no near-term binary catalyst and a long wait for investors.
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 succeeds, an NDA submission would likely follow in late 2027 or 2028, with potential FDA approval in 2028-2029, assuming standard review timelines.

osavampator Updated Nov 3

What to watch

The next major catalyst is the Phase 3 topline readout for osavampator in MDD, expected in the second half of 2027. Positive data would validate a novel AMPA-receptor mechanism in depression and open a large adjunctive-MDD market opportunity. Negative data would remove a key pipeline growth driver but would not threaten Neurocrine's existing INGREZZA franchise. Watch for interim updates or trial-completion announcements from ClinicalTrials.gov (NCT06786624, estimated primary completion July 2027).

Bull case
  • Phase 2 SAVITRI data showed statistically significant and clinically meaningful MADRS score reductions (4.3-point at Day 28, 7.5-point at ~2 months) with a favorable safety profile, supporting the mechanism's promise in treatment-resistant depression.
  • Osavampator is the most advanced AMPA receptor PAM in development for depression, targeting a large $15.8B addressable MDD market with significant unmet need for adjunctive therapies.
  • Neurocrine has a strong commercial track record with INGREZZA (>$1B quarterly revenue), providing ample funding for the Phase 3 program without dilution risk.
Bear case
  • Phase 3 trials in depression have high failure rates; positive Phase 2 data does not guarantee Phase 3 success, especially given the modest effect size (4.3-point MADRS separation at Day 28).
  • The pivotal readout is not expected until H2 2027, leaving a long wait with no near-term binary catalysts for this drug specifically.
  • Competing mechanisms for treatment-resistant depression include NMDA antagonists (e.g., ketamine, already approved as Spravato), which could limit osavampator's commercial opportunity even if approved.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. since December 2024.

CRENESSITY crinecerfont Updated Nov 3

What to watch

CRENESSITY is already approved and generating strong sales growth ($211M in Q3 2026, annualizing above $800M). The next catalysts to watch are quarterly sales trajectory, potential European regulatory submission/approval, and any label expansion data readouts at medical conferences. With no binary PDUFA or pivotal readout ahead, the stock's near-term moves will be driven by commercial execution and INGREZZA/VYKAT XR performance rather than a single CRENESSITY catalyst.

Bull case
  • CRENESSITY is the first new treatment for classic CAH in 70 years, offering a steroid-sparing mechanism that directly addresses a large unmet need.
  • Sales are ramping rapidly: $301M in 2025, $153M Q1 2026, $184M Q2 2026, $211M Q3 2026, with the prescriber base nearly tripling year-over-year.
  • The drug enjoys ~80% reimbursement rates and high patient persistency, suggesting durable revenue growth.
Bear case
  • CRENESSITY captured ~10% of its target patient population in its first year ($301M in 2025), and further penetration may slow as the easy-to-reach patients are already on therapy.
  • The CAH market is small (estimated ~$500M-$700M total), limiting CRENESSITY's long-term peak sales ceiling even if it becomes standard of care.
  • Several large institutional holders (Wellington, Millennium, D.E. Shaw) significantly trimmed or nearly exited NBIX positions in Q2 2026, suggesting some smart money sees limited upside.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the U.S. since 2017. No additional regulatory filings are pending for INGREZZA itself.

INGREZZA valbenazine Updated Nov 3

What to watch

INGREZZA is a mature commercial asset with no near-term binary catalyst. Watch for Q4 2026 and full-year 2026 earnings (expected February 2027) for INGREZZA sales trajectory and 2027 guidance. The next major value inflection points for NBIX stock are likely the Phase 3 readouts for osavampator (major depressive disorder) and direclidine (schizophrenia) expected in 2027, not INGREZZA itself.

Bull case
  • INGREZZA continues to deliver strong commercial growth: Q3 2026 sales of $801 million were up 17% year-over-year, and full-year 2026 guidance was raised to $2.9-$2.925 billion.
  • Head-to-head PET imaging data showed INGREZZA achieves nearly two-fold higher VMAT2 target occupancy versus Austedo XR, supporting a differentiated efficacy narrative.
  • Neurocrine expects double-digit volume growth for INGREZZA in 2027, which management believes will more than offset mid-to-high single-digit net pricing headwinds.
Bear case
  • INGREZZA faces patent cliff risk: key patents are challenged by generics, with settlements allowing generic valbenazine entry as early as March 2038, and some patent expirations as early as 2027-2028.
  • A Phase 3 trial (KINECT-DCP) in dyskinetic cerebral palsy failed to meet primary and key secondary endpoints in 2026, closing off a potential label expansion opportunity.
  • The drug faces mid-to-high single-digit net pricing headwinds expected in 2027, which could pressure revenue growth.
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and on the market since March 2025.

VYKAT XR diazoxide choline Updated Nov 3

What to watch

VYKAT XR is already approved and commercializing, so the next major catalyst would be any FDA regulatory action (label update, boxed warning, or withdrawal request) or a formal safety review, none of which is currently scheduled. Watch for FDA communications on the FAERS safety signal, quarterly sales trajectory (Q3 was $107M), and any updates from competitor Aardvark Therapeutics (ARD-101 clinical hold lifted Oct 2026).

Bull case
  • First and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, addressing a major unmet need in a rare disease with no prior pharmacotherapy options.
  • Rapid commercial uptake: Q3 2026 net product sales reached $107 million, up from a pro-forma $94 million full Q2 2026, showing strong patient demand and persistency.
  • Neurocrine has a strong commercial infrastructure and rare disease expertise, having successfully launched INGREZZA and CRENESSITY, which should support VYKAT XR's continued growth.
Bear case
  • Post-marketing safety data shows 7 deaths and over 100 serious adverse events (edema, respiratory and cardiac complications) reported to the FDA FAERS system as of July 31, 2026, per multiple clinician and patient-group statements.
  • A former FDA regulator has publicly called for VYKAT XR to be withdrawn (STAT, Oct 13, 2026), raising the risk of regulatory action such as a boxed warning, label restriction, or worse.
  • The $2.9 billion acquisition price for Soleno looks stretched if safety concerns materially limit the addressable patient population or lead to reimbursement restrictions.
● neutral
Impact
PhasePhase 1
Time to marketIf successful through all clinical phases and FDA review, potential approval would be many years away, likely 2030 or later given Phase 1 initiation in 2026.

NBIP-2118 Updated Nov 3

What to watch

Neurocrine's R&D Day on December 15, 2026 may provide pipeline updates, but NBIP-2118 is early-stage (Phase 1) and unlikely to be a focal point. The next catalyst specific to this drug is initial Phase 1 safety/tolerability data, expected sometime in 2027. Positive data would validate a novel non-incretin obesity mechanism and support the combination strategy with NBIP-1968; negative safety findings would likely end the program quietly given its early stage and small allocation of NBIX's R&D budget.

Bull case
  • NBIP-2118 targets a novel non-incretin pathway (CRF2 receptor) that could differentiate it from the GLP-1 class by preserving lean muscle mass during weight loss, a key unmet need in the obesity market.
  • Neurocrine is pursuing a combination strategy pairing NBIP-2118 with its triple agonist NBIP-1968 (GLP-1/GIP/glucagon), potentially creating a differentiated fixed-dose combination that addresses both weight loss and muscle preservation.
  • The obesity market is projected to grow significantly through 2028; a successful first-in-class therapy with a muscle-sparing profile could capture meaningful share even against established GLP-1 drugs.
Bear case
  • NBIP-2118 is in Phase 1 with initial data not expected until 2027, meaning no near-term catalyst and years from any potential commercial launch.
  • The obesity market is dominated by established GLP-1 drugs from Novo Nordisk and Eli Lilly; a novel first-in-class CRF2 mechanism faces high clinical and commercial risk with no proof-of-concept in humans yet.
  • Neurocrine has no prior experience in metabolic disease; its expertise is in neurology/endocrinology (INGREZZA, CRENESSITY), and the obesity pipeline is early and unproven.
● neutral
Impact
PhasePhase 2a
Time to marketIf successful through Phase 2a, Phase 3, and FDA review, potential approval would likely be several years away (late 2020s or early 2030s at the earliest), given the Phase 2a data readout is not expected until 2028.

NBI-1117570 Updated Nov 3

What to watch

NBI-1117570 is an early-stage (Phase 2a) pipeline asset with no near-term binary catalyst. The next meaningful event is the Phase 2a topline readout, currently estimated for 2028. For NBIX investors, the stock's near-term drivers are commercial execution of INGREZZA, CRENESSITY, and VYKAT XR, plus Phase 3 data from the more advanced sister asset direclidine (NBI-1117568) expected in 2027-2028.

Bull case
  • NBI-1117570 is a dual M1/M4 muscarinic agonist, a mechanism validated by BMS's approved Cobenfy (KarXT), which generated over $10B in peak sales estimates and represents the first new class of schizophrenia drugs in decades.
  • The drug was discovered by Nxera Pharma using its NxWave platform and is the second NxWave-designed muscarinic compound in Neurocrine's portfolio to reach Phase 2, suggesting a systematic platform approach.
  • Neurocrine is a well-capitalized, diversified commercial-stage biotech with Q3 2026 revenue exceeding $1.1B and strong analyst consensus (32 analysts, mean price target $206, 41.9% implied upside), providing ample resources to develop the pipeline.
Bear case
  • NBI-1117570 is early-stage (Phase 2a) with primary completion not expected until August 2027 and topline data in 2028, meaning no near-term catalyst for years.
  • The muscarinic agonist space is increasingly competitive: BMS's Cobenfy (KarXT) was approved in September 2024 as the first schizophrenia drug with this mechanism, and Neurocrine's own more advanced asset direclidine (NBI-1117568) is already in Phase 3, potentially making NBI-1117570 a follow-on compound.
  • Phase 2 schizophrenia trials have a high historical failure rate, and the drug's dual M1/M4 profile carries unknown safety/tolerability risks compared to the M4-selective approach of direclidine.
● neutral
Impact
PhasePhase 2a
Time to marketIf successful through Phase 2 and Phase 3, potential approval would be several years away, likely no earlier than 2030-2032 given the Phase 2a trial's estimated completion in mid-2028.

NBI-567 Updated Nov 3

What to watch

NBI-567 is an early-stage (Phase 2a) program with no binary catalyst for at least 18 months. The next meaningful event is the Phase 2a readout, estimated around May 2028. For NBIX investors, the more important near-term pipeline catalyst is direclidine (NBI-1117568) in Phase 3 for schizophrenia. NBI-567 is a small, early program within a large, profitable commercial-stage biotech.

Bull case
  • NBI-567 targets the M1 muscarinic receptor, which is directly involved in learning and memory circuits, offering a mechanism of action distinct from acetylcholinesterase inhibitors currently used for Alzheimer's.
  • The muscarinic agonist class has been clinically validated by KarXT (xanomeline-trospium), which was FDA-approved for schizophrenia in 2024, demonstrating that M1/M4 agonism can be therapeutically useful with manageable side effects.
  • Neurocrine has deep expertise in CNS drug development and a strong commercial infrastructure (INGREZZA, CRENESSITY, VYKAT XR) that could support a future Alzheimer's launch if the drug succeeds.
Bear case
  • Alzheimer's disease has a high historical failure rate for novel mechanisms in Phase 2, and muscarinic agonists have previously struggled with tolerability (e.g., xanomeline's cholinergic side effects).
  • The Phase 2a trial is small (135 patients) and only 12 weeks long, which may not be sufficient to demonstrate a convincing cognitive signal.
  • NBI-567 is one of several muscarinic assets in Neurocrine's pipeline (alongside direclidine in Phase 3 and NBI-1117570 in Phase 2), so it may not receive priority resources if other programs show stronger data.
● neutral
Impact
PhasePhase 1
Time to marketYears away, if successful. The drug is in Phase 1 safety testing with no disclosed completion timeline. Typical obesity drug development from Phase 1 to FDA approval takes 5-8 years.

NBIP-1968 Updated Nov 3

What to watch

NBIP-1968 is too early-stage (Phase 1, initiated August 2026) to drive a near-term share-price move for NBIX. Watch for Phase 1 safety/tolerability data readouts, but no specific date has been disclosed. The more relevant catalysts for NBIX in the next 12 months are commercial execution of its approved products (INGREZZA, CRENESSITY, VYKAT XR) and any pipeline updates from its more advanced neurology/psychiatry programs.

Bull case
  • Neurocrine has a strong track record of drug development and commercialization, with three approved products generating over $1.1B in quarterly revenue, providing ample resources to fund the obesity pipeline.
  • NBIP-1968 is designed for fixed-dose combination with Neurocrine's proprietary CRF2 agonist NBIP-2118, potentially offering a differentiated muscle-sparing weight-loss profile versus existing incretins.
  • The global obesity drug market is projected to be worth tens of billions annually, so even a modest share could represent significant upside if NBIP-1968 eventually succeeds through Phase 2/3.
Bear case
  • NBIP-1968 is a 'me-too' triple agonist entering a field already dominated by Eli Lilly's retatrutide, which is in Phase 3 with 28.7% mean weight loss data and head-to-head wins against Ozempic. Neurocrine is years behind.
  • The Phase 1 trial only evaluates single ascending doses for safety/tolerability; no efficacy data or weight-loss numbers have been disclosed, making differentiation from competitors impossible to assess.
  • Obesity is an intensely competitive space with Novo Nordisk, Eli Lilly, and dozens of other biotechs. A Phase 1 entrant with no clear differentiation faces high clinical and commercial risk.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Dec 13, 2024CRENESSITYApproval+4.9%+6.8%
Apr 30, 2024INGREZZAApproval+3.0%+3.1%
Apr 11, 2017INGREZZAApproval+28.5%+28.8%

Clinical trials

11 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
NBI-921352Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEEPhase 2Terminated8Nov 12, 2025
INGREZZAOpen-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseasePhase 3Terminated154Nov 5, 2025
INGREZZAStudy to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyPhase 3Completed86Oct 16, 2025
NBI-1070770A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderPhase 2Completed73Jul 25, 2025
ChronocortComparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaPhase 3Completed · results55Feb 2, 2024
ChronocortChronocort Versus Plenadren Replacement Therapy in Adults With Adrenal InsufficiencyPhase 2Completed58Oct 18, 2023
HydrocortisoneA Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAHPhase 3Completed · results91Jul 13, 2022
Infacort®Extension Study for Patients Entered Into Study Infacort 003Phase 3Completed · results18Aug 10, 2018
Chronocort®Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal HyperplasiaPhase 3Completed · results122Jul 28, 2018
Infacort®Treatment of Adrenal Insufficiency in ChildrenPhase 3Completed · results24Jul 2016
Hydrocortisone Modified Release CapsulesPilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAHPhase 2Completed · results16Dec 2013